Evidence map›Paper›PMID 36411567›Full record

Trial reportCurrent neuropharmacology2023

Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.

Yiguo Tang, Yulu Wu, Xiaojing Li, QinJian Hao, Wei Deng, Weihua Yue, Hao Yan, Yamin Zhang, Liwen Tan, Qi Chen and 25 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Current neuropharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 1 country.

Yiguo TangMental Health Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Yulu WuMental Health Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Xiaojing LiDepartment of Neurobiology, Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
QinJian HaoThe Center of Gerontology and Geriatrics, West China Hospital of Sichuan University, Chengdu, China.
Wei DengDepartment of Neurobiology, Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Weihua YuePeking University Sixth Hospital, Institute of Mental Health, Beijing, China.
Hao YanPeking University Sixth Hospital, Institute of Mental Health, Beijing, China.
Yamin ZhangDepartment of Neurobiology, Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Liwen TanDepartment of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qi ChenDepartment of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Guigang YangBeijing Anding Hospital, Institute for Brain Disorders, Capital Medical University, Beijing, China.
Tianlan LuPeking University Sixth Hospital, Institute of Mental Health, Beijing, China.
Lifang WangPeking University Sixth Hospital, Institute of Mental Health, Beijing, China.
Fude YangBeijing HuiLongGuan Hospital, Beijing, China.
Fuquan ZhangWuxi Mental Health Center, Nanjing Medical University, Wuxi, China.
Jianli YangInstitute of Mental Health, Tianjin Anding Hospital, Tianjin, China.
Keqing LiHebei Mental Health Center, Baoding, Hebei, China.
Luxian LvSecond Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Qingrong TanDepartment of Psychiatry, Xijing Hospital, Fourth Military Medical University, Xi'an, Shanxi, China.
Hongyan ZhangWuxi Mental Health Center, Nanjing Medical University, Wuxi, China.
Xin MaBeijing Anding Hospital, Institute for Brain Disorders, Capital Medical University, Beijing, China.
Lingjiang LiDepartment of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chuanyue WangBeijing Anding Hospital, Institute for Brain Disorders, Capital Medical University, Beijing, China.
Xiaohong MaMental Health Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Dai ZhangPeking University Sixth Hospital, Institute of Mental Health, Beijing, China.
Hao YuDepartment of Psychiatry, Jining Medical University, Jining, China.
Liansheng ZhaoMental Health Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Hongyan RenMental Health Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Yingcheng WangMental Health Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Guangya ZhangDepartment of Psychiatry, Suzhou Psychiatric Hospital, Suzhou, China.
Chuanwei LiDepartment of Psychiatry, Suzhou Psychiatric Hospital, Suzhou, China.
Xiangdong DuDepartment of Psychiatry, Suzhou Psychiatric Hospital, Suzhou, China.
Xun HuThe Clinical Research Center and the Department of Pathology, Affiliated Second Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Tao LiDepartment of Neurobiology, Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Qiang WangMental Health Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Sichuan University · CNCapital Medical University · CNHangzhou Seventh Peoples Hospital · CNPeking University Sixth Hospital · CNWest China Hospital of Sichuan University · CNCentral South University · CNPeking University · CNSuzhou Guangji Hospital · CNAir Force Medical University · CNBeijing HuiLongGuan Hospital · CNHebei Mental Health Center · CNHenan Psychiatric Hospital · CNJining Medical University · CNNanjing Medical University · CNSecond Affiliated Hospital of Zhejiang University · CNSecond Xiangya Hospital of Central South University · CNSoochow University · CNTianjin Medical University General Hospital · CNWuxi People's Hospital · CNZhejiang University · CN

Funding

1.3.5 Project for Disciplines of Excellence of the West China Hospital, Sichuan University ZY2016103, ZY2016203Introduction Project of Suzhou Clinical Expert Team SZYJTD201715National Key Research and Development Program of the Ministry of Science and Technology of China 2016YFC0904300, 2016YFC1201700National Nature Science Foundation of China 81630030, 81920108018, 81771446, 82171499"Pioneer" and "Leading Goose" R&D Program of Zhejiang 2022C03096Project for Hangzhou Medical Disciplines of Excellence & Key Project for Hangzhou Medical Disciplines 202004A11
6 · The paper itself

Abstract

backgroundSince the early clinical efficacy of antipsychotics has not yet been well perceived, this study sought to decide whether the efficacy of antipsychotics at week 2 can predict subsequent responses at week 6 and identify how such predictive capacities vary among different antipsychotics and psychotic symptoms.

methodsA total of 3010 patients with schizophrenia enrolled in a randomized controlled trial (RCT) and received a 6-week treatment with one antipsychotic drug randomly chosen from five atypical antipsychotics (risperidone 2-6 mg/d, olanzapine 5-20 mg/d, quetiapine 400-750 mg/d, aripiprazole 10-30 mg/d, and ziprasidone 80-160 mg/d) and two typical antipsychotics (perphenazine 20-60 mg/d and haloperidol 6-20 mg/d). Early efficacy was defined as the reduction rate using the Positive and Negative Syndrome Scale (PANSS) total score at week 2. With cut-offs at 50% reduction, logistic regression, receiver operating characteristic (ROC) and random forests were adopted.

resultsThe reduction rate of PANSS total score and improvement of psychotic symptoms at week 2 enabled subsequent responses to 7 antipsychotics to be predicted, in which improvements in delusions, lack of judgment and insight, unusual thought content, and suspiciousness/ persecution were endowed with the greatest weight.

conclusionIt is robust enough to clinically predict treatment responses to antipsychotics at week 6 using the reduction rate of PANSS total score and symptom relief at week 2. Psychiatric clinicians had better determine whether to switch the treatment plan by the first 2 weeks.

Indexed as

Antipsychotic AgentsSchizophreniaAripiprazoleBenzodiazepinesHaloperidolHumansOlanzapinePiperazinesQuetiapine FumarateRisperidoneThiazolesTreatment OutcomeAntipsychotic AgentsAripiprazoleBenzodiazepinesHaloperidolOlanzapinePiperazinesQuetiapine FumarateRisperidoneThiazolesziprasidoneAntipsychoticsearly efficacypredictive capacityRCTschizophreniasubsequent response

Identifiers

PMID36411567
PMCPMC10190139
OpenAlexW4309655301

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.